Isohexane Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is supplied as a branched C6 aliphatic hydrocarbon stream composed predominantly of 2-methylpentane (CAS 107-83-5) with 3-methylpentane (CAS 96-14-0) and a controlled n-hexane fraction. The material is not an active pharmaceutical ingredient and is not retained in finished tablets, capsules, granules, or injectable solutions; it functions as a low-boiling process solvent, extraction medium, and crystallization antisolvent where moisture contact would alter the hydrate state or polymorphic form of the active. The grade is supplied under configurations IPH-PG-2.5, IPH-PG-20, IPH-PG-200, and IPH-PG-1000, corresponding to 2.5 L inert-liner glass bottles, 20 L stainless steel pails, 200 L stainless steel drums, and 1000 L stainless steel intermediate bulk containers. For injectable API processing, the IPH-PG-I suffix denotes the reduced-endotoxin, reduced-particulate specification handled under nitrogen in clean-room transfer stations. The product is released with a certificate of analysis and a declaration of ICH Q3C residual-solvent status, and it is controlled under pharmaceutical quality systems rather than as a general-purpose industrial solvent.

What release limits and residual-solvent classification apply to the branched C6 stream?

Release criteria for the pharma-grade stream are set by gas chromatographic purity, aromatic content, water, non-volatile residue, and peroxide control. The values in the table below are typical release limits; individual site quality agreements may tighten these limits where the solvent is used in later steps of injectable API synthesis. The material does not receive a specific ICH Q3C class assignment because 2-methylpentane and 3-methylpentane are not listed as harmonized Class 2 or Class 3 solvents. Residual levels therefore require a site-specific justification under the general provisions of ICH Q3C for solvents without a harmonized permitted daily exposure. The specification is not equivalent to n-heptane, which is Class 3, and cannot be interchanged with n-hexane, which is Class 2.

Because n-hexane is a controlled impurity in this product, the n-hexane ceiling is set at ≤ 0.1% rather than allowing an undistinguished C6 isomer distribution. This control directly lowers the neurotoxicologic risk associated with the metabolic formation of 2,5-hexanedione from n-hexane. A higher n-hexane content would shift the residual-solvent assessment toward the Class 2 PDE of 2.9 mg/day for n-hexane, whereas the branched C6 stream must be justified by process capability and toxicological evaluation because no harmonized PDE is assigned.

In fluid-bed and high-shear granulation lines, isohexane is applied only in explosion-rated processing suites because the closed-cup flash point is below -20 °C and the lower explosive limit is approximately 1.2 vol% in air. Vessel oxygen concentration is maintained below 5 mol% by nitrogen inerting, and LEL sensors are interlocked to spray valves at 25% LEL. The solvent’s surface tension of approximately 18 mN/m at 20 °C gives rapid wetting of microcrystalline cellulose, dibasic calcium phosphate, and starch agglomerates, but it does not dissolve PVP or HPMC. Binder systems are therefore selected from ethylcellulose, methacrylic acid copolymers, or low-molecular-weight rosin derivatives dissolved in a suitable co-solvent. On a 600 L high-shear granulator, wet massing torque is used to close the endpoint because the low boiling point makes evaporative loss measurable during the wet phase. Spray rates above 1.2 kg/min have produced overwet masses and delayed discharge in production batches; however, published data for this specific configuration is limited, and scale-up should be based on spray flux and impeller tip speed rather than linear geometric similarity.

Residual solvent removal is governed by drying air dew point and granule D50

Residual solvent removal depends on the granule size distribution, inlet air dew point, and exhaust humidity. The atmospheric boiling range of 60–62 °C permits vacuum or fluid-bed drying at 40–50 °C. Under these conditions, uncoated granules with D50 250–400 µm typically reach below 500 ppm residual isohexane within 20–40 min when the inlet air dew point is below 0 °C. This typical value is not a release limit; each batch must be tested by headspace gas chromatography using USP <467> or Ph. Eur. 2.4.24 before tableting or encapsulation. At relative humidity above 60%, the facility should pre-dry the granulation room air and keep the product hopper under nitrogen because moisture condensation on chilled granule surfaces causes agglomerate bridging. A terminal drying endpoint below 100 ppm may be required for APIs targeted at pediatric or injectable matrices, depending on the in-house permitted daily exposure derived from maximum daily dose and toxicological qualification. Cleaning validation relies on solvent-wetted rinse samples and closed-loop headspace measurement; visual cleanliness is not sufficient because isohexane evaporates rapidly and can leave low-level residues invisible on stainless steel surfaces.

When the solvent enters injectable API purification, endotoxin and particulate limits supersede oral-grade criteria

Only the injectable-grade configuration with a release endotoxin limit of <0.25 EU/mL is qualified for use in the purification of injectable APIs. The solvent is used as a crystallization antisolvent, extraction medium, or chromatographic mobile phase component in downstream steps; it is not injected and must be removed by vacuum distillation at 50–60 °C jacket temperature and 20–50 mbar vacuum, followed by nitrogen-assisted drying. Filter compatibility studies with 0.2 µm hydrophobic PTFE or 316L stainless steel filter membranes show no detectable extractables increase when the solvent is pre-filtered; silicone and natural rubber elastomers swell and are not used. Residual solvent in the final injectable API is tested by headspace GC-MS with a reporting threshold of 1 ppm. If isohexane is below the reporting threshold, it is excluded from the finished product solvent calculation; if detected above threshold, a toxicologically qualified limit is applied because an ICH Q3C PDE is not available for this solvent. Parenteral product manufacturers should also verify that the solvent’s low aqueous miscibility does not create phase separation during buffer dilution steps in downstream purification.

Branched-vs-linear C6 substitution effects in crystallization work-up

Substitution of isohexane for n-hexane changes the evaporation rate, distillation profile, and residual-solvent risk. The atmospheric boiling range is approximately 8 °C lower than n-hexane, so vacuum levels that previously avoided product degradation may need adjustment to prevent uncontrolled nucleation. Crystallization yield and crystal habit may shift because branched C6 isomers have a slightly lower solvency for highly lipophilic impurities; a solvent ratio increase of 10–20% is sometimes observed when matching impurity rejection at the same batch temperature. Published data for this specific API-by-API comparison is limited; process development should use focused beam reflectance measurements and polymorph screens rather than assuming equivalence. Toxicologically, the branched C6 stream offers a different profile from n-hexane. n-Hexane is converted to the metabolite 2,5-hexanedione, which is linked to peripheral neuropathy; 2-methylpentane does not form this metabolite at comparable rates. Nevertheless, all C6 aliphatic hydrocarbons depress the central nervous system at high exposure, and the material remains highly flammable.

Storage and material compatibility are governed by flammability and purity retention. Bulk tanks are 316L stainless steel with pressure/vacuum relief and nitrogen blanketing; carbon steel is not used because moisture ingress creates iron contamination that appears as visible particulate on filter membranes. The product is incompatible with strong oxidizers, halogens, and concentrated nitric acid. Containers should be resealed under nitrogen after use and retested for peroxide accumulation after cumulative air exposure; peroxide formation in aliphatic hydrocarbons is slow, but the presence of dissolved oxygen and light can accelerate degradation in partially emptied containers. Automated drum pumps with 1.5 m PTFE dip tubes are used to avoid splash filling and static discharge; grounding resistance is checked to stay below 10⁶ Ω according to site electrostatic safety procedures.